Japan has officially launched a public comment period for its landmark cannabis reform bill, offering new details on how its nascent cannabis industry will look over the coming months.
On May 30, the Japanese government announced that it would now be accepting public comments from interested parties on five measures of the new bill.
Most notably, the preliminary proposals suggest that Japan is seeking to forgo the complex and lengthy Novel Foods process for CBD products, and could become the first country to approve CBD in food.
Yves Antoniazzi, Managing Director of Astrasana Holding AG, one of the few international companies to have a foothold in the Japanese CBD market, said: “We have been waiting a long time for this. It is a huge milestone for the global cannabis industry. Japan is the one of the first countries to approve CBD in food, paving the way for corporate companies to list CBD products in retail chains.”
Business of Cannabis will be digging deeper into the details of Japan’s new proposals and providing analysis into their implications for businesses in the coming days.
What happened?
Late last year, Japan made a major step towards cannabis reform after approving a bill to amend its 75-year-old Cannabis Control Act.
After passing the bill in November, the Japanese authorities have been ironing out the details of these reforms, and the industry has been poised for an announcement from the Ministry of Health, Labour and Welfare (MHLW) laying out the new framework.
The public comment period, which will last until June 13 or 29, offers medical professionals and CBD businesses the opportunity to examine the draft order and voice their concerns before a final decision is made and the amendments can be enacted.
Opinions are now being solicited on five topics, including law enforcement, THC analysis methods, the development of related laws and regulations, and first and second-class cultivation license reviews.
As previously reported, the bill is set to amend a few key measures which could enable the country’s CBD and medical cannabis industries to flourish.
Primarily, while Japan already has a booming CBD industry, it currently only allows products with no trace THC. This is expected to change, and initial reports suggest this could rise to 0.3%.
‘Huge Milestone’ as Japan Moves Ahead With Cannabis Reform
Japan has officially launched a public comment period for its landmark cannabis reform bill, offering new details on how its nascent cannabis industry will look over the coming months.
On May 30, the Japanese government announced that it would now be accepting public comments from interested parties on five measures of the new bill.
Most notably, the preliminary proposals suggest that Japan is seeking to forgo the complex and lengthy Novel Foods process for CBD products, and could become the first country to approve CBD in food.
Yves Antoniazzi, Managing Director of Astrasana Holding AG, one of the few international companies to have a foothold in the Japanese CBD market, said: “We have been waiting a long time for this. It is a huge milestone for the global cannabis industry. Japan is the one of the first countries to approve CBD in food, paving the way for corporate companies to list CBD products in retail chains.”
Business of Cannabis will be digging deeper into the details of Japan’s new proposals and providing analysis into their implications for businesses in the coming days.
What happened?
Late last year, Japan made a major step towards cannabis reform after approving a bill to amend its 75-year-old Cannabis Control Act.
After passing the bill in November, the Japanese authorities have been ironing out the details of these reforms, and the industry has been poised for an announcement from the Ministry of Health, Labour and Welfare (MHLW) laying out the new framework.
The public comment period, which will last until June 13 or 29, offers medical professionals and CBD businesses the opportunity to examine the draft order and voice their concerns before a final decision is made and the amendments can be enacted.
Opinions are now being solicited on five topics, including law enforcement, THC analysis methods, the development of related laws and regulations, and first and second-class cultivation license reviews.
As previously reported, the bill is set to amend a few key measures which could enable the country’s CBD and medical cannabis industries to flourish.
Primarily, while Japan already has a booming CBD industry, it currently only allows products with no trace THC. This is expected to change, and initial reports suggest this could rise to 0.3%.
Organigram Signs 2nd UK Supply Deal With Avida Medical
Next PostCanopy Growth Trims Losses Significantly as It Prepares for Financial Boost From Rescheduling
Ben Stevens
Editor and Journalist with more than seven years experience reporting on business and financial sectors.
Related Posts
Related Posts
What Could Trudeau’s Exit Mean for Cannabis in Canada?
Canada’s Prime Minister, Justin Trudeau, announced last week that he plans to step down as leader of the Liberal Party...
Medical or Recreational? Bedrocan Calls for Stricter Medical Market Regulation From New German Government
The increasingly blurry lines between Germany’s medical and recreational cannabis markets are continuing to cause conflict among lawmakers and industry...
Tilray Wins Tender to Supply Luxembourg, Argent Biopharma Completes Capital Raise, & More from Stenocare
Immediate Investigation into DEA’s Conduct Demanded Ahead of Rescheduling Hearings Amid Fresh Allegations of Bias
Finance Experts Mixed on Prospects of Cannabis Capital Infusion Post-Rescheduling
France’s New Health Minister Extends Medical Cannabis Programme Again, But Patients Urged to Seek Alternative Treatment
CONNECT
Related Posts
Related Posts
What Could Trudeau’s Exit Mean for Cannabis in Canada?
Canada’s Prime Minister, Justin Trudeau, announced last week that he plans to step down as leader of the Liberal Party...
Medical or Recreational? Bedrocan Calls for Stricter Medical Market Regulation From New German Government
The increasingly blurry lines between Germany’s medical and recreational cannabis markets are continuing to cause conflict among lawmakers and industry...
Tilray Wins Tender to Supply Luxembourg, Argent Biopharma Completes Capital Raise, & More from Stenocare
Argent BioPharma Argent Biopharma (previously MGC Pharmaceuticals) has completed a US$4.5 million capital raise to support its drug development...
Immediate Investigation into DEA’s Conduct Demanded Ahead of Rescheduling Hearings Amid Fresh Allegations of Bias
The Drug Enforcement Administration (DEA) has come under renewed pressure to be removed from the upcoming cannabis rescheduling process amid...
Finance Experts Mixed on Prospects of Cannabis Capital Infusion Post-Rescheduling
Reaching consensus on hotly debated issues is rare in the cannabis space, especially when it comes to potential ramifications of...
Recent Posts
Related Posts
UK Regulators Signal Goal for ‘Zero Detectable THC’ in CBD Products in Worrying Signs for Full Spectrum Advocates
This week, the UK Food Standards Agency (FSA) held its monthly board meeting to discuss, among other things, the future...
Japan’s CBD Industry Recieves First Investments From Publicly Listed Companies Following Recent Reforms
AstraSana Japan Co., Ltd. has formed a capital and business alliance with Japan’s GSI Creos Corporation, bolstered by their investment....
Shaping Germany’s Cannabis Future: Insights from the Berlin Executive Summit
Last week, the Business of Cannabis: Berlin Executive Summit welcomed over 150 executives, policymakers, and thought leaders to take stock...
UK CBD Industry Sees Light at the End of the Tunnel: First Authorised Products Expected by Spring 2025
In a long-awaited and major step forward for the UK’s CBD sector, the regulator has announced a new roadmap that...
Ananda Aiming to ‘Meet Regulators at Their Point of Need’ As it Secures More Major UK Clinical Cannabis Trials
UK-based biotech firm Ananda Developments has solidified its position as a driving force in clinical cannabis research in Europe, announcing...
Subscribe to our mailing list to receives daily updates!
We won’t spam you
Categories
Browse by Tags